{"nctId":"NCT03463993","briefTitle":"Efficacy of Tranexamic Acid in Preventing Postpartum Haemorrhage After Elective Caesarean Section","startDateStruct":{"date":"2018-04-08","type":"ACTUAL"},"conditions":["Post Partum Hemorrhage"],"count":506,"armGroups":[{"label":"Group A","type":"EXPERIMENTAL","interventionNames":["Drug: Tranexamic Acid","Drug: Oxytocin"]},{"label":"Group B","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Oxytocin"]}],"interventions":[{"name":"Tranexamic Acid","otherNames":["TXA"]},{"name":"Oxytocin","otherNames":["Prophylactic oxytocin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Pregnant woman with signed informed consent\\*\\*\\*\n* Understand English and/or Shona\n* Estimated gestational age of 38 weeks or older\n* Requiring Elective Caesarean Section defined as caesarean section performed before onset of labour\n* Live intrauterine fetus\n\n  * The study will enrol participants who are Pregnant and who have a signed informed Consent form. Some of the pregnant women may be minors as they are occasionally included in patients planned for elective caesarean section for varying indications. Their inclusion also will make the results of the trial generalizable to elective caesarean section patients attended to at the two study hospitals. Consent will be sought from a legally authorized representative such as the parent or guardian.\n\nExclusion Criteria:\n\n* Placental Abruption\n* Emergency caesarean section\n* Current or previous history of significant disease including heart disease, liver, renal disorders\n* Known coagulopathy or history of deep venous thrombosis and/or pulmonary embolism, or arterial thrombosis (angina pectoris, myocardial infarction, stroke)\n* History of epilepsy or seizures\n* Autoimmune disease\n* Sickle cell disease\n* Severe haemorrhagic disease\n* Intrauterine fetal demise\n* Eclampsia/HELLP syndrome\n* Administration of anticoagulants - clexane or antiplatelet agents in the week prior to delivery","healthyVolunteers":true,"sex":"FEMALE","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Postpartum Haemorrhage (PPH)","description":"PPH based on Haematocrit calculation and PPH based on Haemoglobin calculation","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"71","spread":null}]}]}]},{"type":"SECONDARY","title":"Estimated Blood Loss","description":"Blood loss during caesarean section based on visual estimation and calculation.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"483.73","spread":"182.56"},{"groupId":"OG001","value":"479.61","spread":"139.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"650.06","spread":"631.50"},{"groupId":"OG001","value":"653.05","spread":"796.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"644.30","spread":"692.27"},{"groupId":"OG001","value":"707.68","spread":"948.01"}]}]}]},{"type":"SECONDARY","title":"Amount of Blood Transfused","description":"Requirement by participant of blood transfusion","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":null},{"groupId":"OG001","value":"2.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Use of Additional Uterotonics","description":"Number of participants who received additional uterotonics such as an oxytocin infusion or prostaglandin (misoprostol).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Tranexamic Acid Side Effects","description":"Number of participants with adverse effects related to tranexamic acid use","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Requiring Emergency Surgery for PPH","description":"Number of participants requiring emergency surgical procedures to manage any PPH that occurs","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Days of Participants' Hospital Stay","description":"The number of days the participant stayed in hospital from the date of admission to date of discharge from hospital.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Neonatal Outcome - Weight","description":"Neonatal birth weight in grams","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3087.85","spread":"523.98"},{"groupId":"OG001","value":"3109.98","spread":"513.13"}]}]}]},{"type":"SECONDARY","title":"Neonatal Outcome - APGAR Score of the Neonates at 1 Minute and 5 Minutes After Delivery","description":"APGAR (Appearance, Pulse, Grimace, Activity, Respiration) scores out of 10 at 1 minute and 5 minutes. A measure of the physical condition of a newborn infant. It is obtained by adding points (maximum score of 2, 1, or 0 as minimum score) for Appearance (0 - blue/pale, 1 - pink body, blue extremities, 2 - pink); Pulse (0 - absent heart rate, 1 - below 100 beats per minute, 2 - over 100 beats per minute), Grimace (Reflex irritability - 0 - floppy, 1 - minimal response to stimulation, 2- prompt response to stimulation), Activity (muscle tone: 0 - absent, 1 - Flexed arms and legs, 2 - active), Respiration ( 0 - absent, 1 - slow or irregular, 2 - vigorous cry). APGAR score at 1minute or 5 minute can be a minimum of of 0 (0+0+0+0+0) or maximum of 10 (2 for each parameter above).","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Neonatal Outcome - Number of Neonates Admitted to the Neonatal Unit","description":"Number of neonates requiring admission to the neonatal unit from time of delivery at caesarean section","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"Neonatal Outcome - Number of Neonates Diagnosed With Jaundice","description":"Number of neonates with clinical jaundice (yellowing of the skin or whites of the eyes)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Neonatal Outcome - Thromboembolic Event","description":"Number of neonatal thromboembolic events","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Neonatal Outcome - Death","description":"Neonatal death that occurs","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":224},"commonTop":["Hypotension","Headache","Nausea","Vomiting"]}}}